🔗 Share this article

Chancellor Rachel Reeves has announced she is preparing "targeted measures to address cost of living issues" in the forthcoming financial statement.

Speaking to the BBC, she noted that lowering price rises is a shared task of both the administration and the central bank.

The UK's inflation rate is projected to be the most elevated among the G7 developed nations this year and the following year.

Possible Utility Bill Interventions

Sources suggest the government could intervene to reduce energy bills, for example by cutting the present 5% level of value-added tax charged on energy supplies.

Another option is to cut some of the policy costs currently included in household expenses.

Fiscal Limitations and Expert Predictions

The administration will obtain the latest draft from the official forecaster, the Office for Budget Responsibility, on Monday, which will show how much space there is for these actions.

The consensus from the majority of analysts is that the Chancellor will have to declare tax increases or expenditure reductions in order to meet her self-imposed fiscal targets.

Earlier on the same day, calculations showed there was a twenty-two billion pound shortfall for the chancellor to fill, which is at the more modest range of projections.

"There's a shared responsibility between the Bank of England and the government to further reduce some of the causes of inflation," the Chancellor told the BBC in Washington, at the conferences of the IMF and World Bank.

Tax Commitments and International Concerns

While much of the attention has been on probable tax increases, the chancellor said the latest information from the OBR had not altered her vow to election pledges not to increase tax levels on income tax, VAT or social security contributions.

She attributed an "uncertain global environment" with increasing geopolitical and commercial tensions for the Budget tax moves, probably to be targeted on those "with the broadest shoulders."

International Economic Tensions

Addressing apprehensions about the United Kingdom's commercial links with the Asian nation she said: "Our national security always are paramount."

Last week's statement by Chinese authorities to increase export controls on critical minerals and other materials that are essential for high-technology manufacturing led American leader Donald Trump to threaten an further 100% import tax on goods from China, raising the prospect of an full-scale commercial conflict between the two economic giants.

The US Treasury Secretary called China's move "commercial pressure" and "a global supply chain control attempt."

Inquired about considering the US offer to participate in its dispute with the Asian nation, the Chancellor said she was "deeply worried" by Chinese actions and encouraged the Chinese government "to avoid restrictions and restrict access."

She said the move was "damaging for the world economy and creates further obstacles."

"In my view there are fields where we should confront China, but there are also important chances to sell into China's economy, including financial services and other sectors of the economy. We've got to maintain that balance appropriate."

The Treasury chief also stated she was working with international partners "regarding our own essential resources strategy, so that we are reduced dependence."

Health Service Drug Costs and Funding

The Chancellor also admitted that the cost the National Health Service spends on medicines could rise as a consequence of current talks with the Trump administration and its pharmaceutical firms, in exchange for lower tariffs and funding.

A number of the world's largest pharmaceutical manufacturers have said in recent statements that they are either halting or canceling projects in the United Kingdom, with some attributing the insufficient payments they are receiving.

Last month, the Science Minister said the price the health service spends on drugs would must rise to stop firms and drug research funding leaving the United Kingdom.

Reeves told the BBC: "It has been observed due to the cost structure, that clinical trials, innovative medicines have not been provided in the UK in the way that they are in other EU nations."

"The objective is to guarantee that individuals getting care from the NHS are can receive the top essential drugs in the globe. And so we are looking at all of that, and... seeking to attract additional funding into the UK."